<DOC>
	<DOCNO>NCT02437318</DOCNO>
	<brief_summary>To determine whether treatment alpelisib plus fulvestrant prolongs progression-free survival compare fulvestrant placebo men postmenopausal woman hormone receptor positive ( HR+ ) , HER2-negative advance breast cancer , receive prior treatment Aromatase Inhibitor either ( neo ) adjuvant advance disease .</brief_summary>
	<brief_title>Study Assessing Efficacy Safety Alpelisib Plus Fulvestrant Men Postmenopausal Women With Advanced Breast Cancer Which Progressed After Aromatase Inhibitor Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>If female , patient postmenopausal Patient identify PIK3CA status Patients may : relapse document evidence progression ( neo ) adjuvant endocrine therapy within 12 month completion ( neo ) adjuvant endocrine therapy treatment metastatic disease ; relapse document evidence progression 12 month completion ( neo ) adjuvant endocrine therapy subsequently ; progress document evidence progression one line endocrine therapy metastatic disease ; newly diagnose advanced breast cancer , relapse document evidence progression one line endocrine therapy Patient recurrence progression disease AI therapy ( i.e . letrozole , anastrozole , exemestane ) . Patient histologically and/or cytologically confirm diagnosis estrogenreceptor positive breast cancer local laboratory HER2 negative breast cancer Patient either measurable disease per RECIST 1.1 criterion OR least one predominantly lytic bone lesion must present Patient adequate bone marrow function Patient symptomatic visceral disease disease burden make patient ineligible endocrine therapy per investigator 's best judgment Patient receive prior treatment chemotherapy ( except neoadjuvant/ adjuvant chemotherapy ) , fulvestrant , PI3K , mTOR AKT inhibitor ( pretreatment CDK4/6 inhibitor allow ) Patient inflammatory breast cancer screen Patients Child pugh score B C Patients establish diagnosis diabetes mellitus type I control type II Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 2 Patient CNS involvement unless he/she least 4 week prior therapy completion start study treatment stable CNS tumor time screen receive steroid and/or enzyme induce antepileptic medication brain metastasis Patient participate prior investigational study within 30 day prior enrollment within 5 halflives investigational product , whichever longer Patient history acute pancreatitis within 1 year screen past medical history chronic pancreatitis Patient relapse documented evidence progression 12 month completion ( neo ) adjuvant endocrine therapy treatment metastatic disease Other protocoldefined inclusion/esclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HR+</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>alpelisib</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>PI3K</keyword>
	<keyword>Phase III</keyword>
	<keyword>ER+</keyword>
	<keyword>PgR+</keyword>
	<keyword>men</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>neoplasm</keyword>
</DOC>